Treatment with lurasidone ( vs placebo ) was associated with significantly greater reductions in MADRS scores in the mixed features group ( -15.7 vs -10.9 ; P = .001 ; week 6 ; mixed model for repeated measures [ MMRM ] ; effect size , 0.48 ) and in the group without mixed features ( -15.2 vs -10.8 ; P = .002 ; week 6 ; MMRM ; effect size , 0.48 ) .